A Novel Polymer-Lipid Hybrid Nanoparticle for Efficient Nonviral Gene Delivery

Component: Polymer; Description: Cetylated polyethylenimine (PEI, 600 Da) — provides DNA condensation via electrostatic interactions and endosomal escape via "proton-sponge" effect

Component: Lipid Components; Description: • Egg yolk phosphatidylcholine (EPC) — structural lipid<br>• Triolein — neutral oil core<br>• PEG-DSPE (molar ratio to EPC = 0.05) — PEGylated lipid for stealth properties

Component: Optimal Formulation (L-PLN); Description: Cetylated PEI : Triolein : EPC : PEG-DSPE = 0.1 : 1 : 1 : 0.05 (molar ratio)

Component: Control Formulation (PLN); Description: Cetylated PEI : Triolein : EPC = 0.1 : 1 : 1 (no PEG-DSPE)

Component: Preparation Method; Description: Emulsifying-solvent evaporation: components dissolved in dichloromethane, emulsified with water by sonication, solvent evaporated under reduced pressure at 35°C

Component: Payload; Description: pEGFP-N2 plasmid DNA (enhanced green fluorescent protein reporter)

Component: Complexation; Description: L-PLN mixed with DNA at various N/P (PEI nitrogen/DNA phosphate) ratios; 20 min incubation at 37°C

Component: Key Characteristics; Description: • L-PLN size: ~128 nm (slightly larger than PLN)<br>• L-PLN zeta potential: +35.2 mV (similar to PLN)<br>• L-PLN/DNA complex size (N/P=10): ~240 nm

Component: Targeting; Description: No active targeting ligand described; relies on positive charge for non-specific cellular uptake

Parameter: Cell Models; Details: • HEK293 (human embryonic kidney cells) — 1×10⁵ cells/well in 24-well plates<br>• MDA-MB-231 (human breast cancer cells) — 5×10⁴ cells/well

Parameter: Culture Conditions; Details: RPMI 1640 (HEK293) or DMEM (MDA-MB-231) with 10% FBS, penicillin/streptomycin; serum-free medium 24 h before transfection

Parameter: N/P Ratios Tested; Details: 2, 5, 10, 15, 20, 25 (for transfection efficiency and gel retardation)

Parameter: Transfection Protocol; Details: 1 μg pEGFP-N2/well; complexes added for 4 h at 37°C; medium replaced with complete medium; incubated for additional 48 h

Parameter: Positive Control; Details: Lipofectamine™ 2000/DNA complexes (2 μL Lipofectamine + 1 μg DNA, 20 min incubation at RT) — per manufacturer's protocol

Parameter: Negative Control; Details: Untreated cells (for cytotoxicity, set as 100% viability)

Parameter: Replicates; Details: • Transfection experiments: repeated three times (n=3)<br>• Cytotoxicity assay: n=6<br>• All data expressed as mean ± SD

Analysis Category: Nanoparticle Characterization; Methods: • NICOMP™ ZLS 380 — particle size and zeta potential at 25°C<br>• Gel retardation assay — DNA condensation capacity at various N/P ratios (1% agarose, 100 V, 20 min, ethidium bromide staining)

Analysis Category: Transfection Efficiency; Methods: • Fluorescence microscopy (Zeiss) — GFP expression visualization at 48 h<br>• Fluorescence spectrophotometry — GFP intensity (ex: 493 nm, em: 510 nm) after cell lysis with 1% Triton X-100<br>• Flow cytometry (FACS, BD Biosciences) — percentage of GFP-positive cells using standard gating technique

Analysis Category: Cytotoxicity; Methods: • MTT colorimetric assay — 96-well plate, 1×10⁴ cells/well, 100 ng DNA/200 μL, 24 h post-transfection; absorbance at 570 nm (BioTek ELx800)

Analysis Category: Statistical Analysis; Methods: • One-way ANOVA; Student-Newman-Keuls test for pair-wise comparisons<br>• SPSS version 13.0<br>• Two-tailed P < 0.05 considered statistically significant

Parameter: Particle size; PLN: 128 nm; L-PLN: ~128 nm (slight increase)

Parameter: Zeta potential; PLN: ~+35 mV; L-PLN: +35.2 mV (no significant change)

Parameter: L-PLN/DNA complex size (N/P=10); PLN: -; L-PLN: ~240 nm

Parameter: Complete DNA retardation; PLN: N/P ≥ 10; L-PLN: N/P ≥ 10

Formulation: Lipofectamine™ 2000; HEK293 (% GFP+): ~19.3%; MDA-MB-231 (% GFP+): ~18.5%

Formulation: PLN/DNA (N/P=10); HEK293 (% GFP+): ~21.9%; MDA-MB-231 (% GFP+): ~20.1%

Formulation: L-PLN/DNA (N/P=10); HEK293 (% GFP+): ~37.2%; MDA-MB-231 (% GFP+): ~34.3%

• L-PLN transfection efficiency was significantly higher than both PLN and Lipofectamine™ 2000 (P < 0.05 and P < 0.01, respectively)
• Optimal N/P ratio = 10 for both L-PLN and PLN formulations; efficiency decreased at higher N/P ratios
• GFP expression reached maximum at days 2–4 post-transfection

1. In vitro only: The authors acknowledge that "the results from in vitro transfection showed transfection with L-PLN formulation was more efficient and less toxic" but state that "needs further in vivo study." No in vivo biodistribution, circulation half-life, or therapeutic efficacy data are provided.

2. Mechanistic speculation: The enhanced transfection is attributed to the PEG protective layer reducing lysosomal degradation; however, this mechanism is postulated rather than experimentally demonstrated (no lysosomal degradation assays, no PEG density optimization, no mechanistic tracking of DNA fate).

3. Serum stability not evaluated: Although L-PLN is described as a "long circulating" formulation, serum stability and transfection efficiency in the presence of serum were not tested — a critical parameter for in vivo relevance.

4. Limited cell line panel: Only two cell lines (HEK293 and MDA-MB-231) were tested; no evaluation in hard-to-transfect primary cells, immune cells, or stem cells.

5. Cargo limitation: Only pEGFP-N2 plasmid DNA (reporter gene) was delivered; no therapeutic gene (e.g., tumor suppressor, suicide gene, CRISPR components) was tested for functional outcome beyond reporter expression.

6. No active targeting: Lacking targeting ligands for cell-specific delivery; this may limit in vivo application where off-target delivery is a concern.

7. PEI molecular weight: Uses cetylated PEI (600 Da), which is a low molecular weight modification; while this may reduce toxicity, high molecular weight PEI (25 kDa) typically shows higher transfection efficiency — the trade-off with lower molecular weight is acknowledged but not directly compared.

8. Optimal N/P ratio determined only for two cell lines: The optimal N/P ratio of 10 may not translate to other cell types or in vivo conditions.

9. No comparison to other PEGylated lipid systems: The study focuses solely on PEG-DSPE; no comparison to other PEG-lipid conjugates (e.g., PEG-DOPE) or different PEG chain lengths.

10. Cytotoxicity assay timing: MTT assay performed at 24 h post-transfection only; long-term toxicity and cumulative effects were not assessed.

Report prepared based on the published Acta Pharmacologica Sinica article. For full experimental details and supplementary information, please refer to the original publication.